Popular coffee creamer recalled due to illness and spoilage complaints
A coffee creamer brand has recalled over 75,000 bottles after receiving complaints of 'spoilage and illness.'
Danone, the parent company of International Delight coffee creamer, originally issued a voluntary recall on February 21. On Wednesday, the United States Food and Drug Administration upgraded the recall to its second-highest risk level, a Class II recall.
According to the FDA, a Class II recall means using or being exposed to the product may 'cause temporary or medically reversible adverse health consequences.'
The recall only applies to two specific flavors of the coffee creamer: 32-ounce bottles of Hazelnut creamer and 32-ounce bottles of Cinnabon Classic Cinnamon Roll. The total number of recalled creamer bottles was 75,054.
Their expiration dates are listed as July 2, 2025, and July 3, 2025, respectively. Both recalled bottles have a producing plant code of 51-4114 R-S.
Thirty-one states received shipments of the creamer bottles: Alabama, Arkansas, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, Maine, Michigan, Minnesota, Missouri, Mississippi, North Carolina, Nebraska, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Wisconsin, and Wyoming.
'A limited number of these products did not meet our quality standards, due to premature spoilage manifesting as a texture issue,' a representative from Danone North America, told Today.com in a statement.
'While we know this is disappointing for our creamer fans, testing data has confirmed that this is not a food safety issue. We chose to voluntarily recall these isolated products out of an abundance of caution while we address the quality issue.'
Throughout 2025, various food products have been recalled including one popular lemonade brand that received an update to its recall last week to reflect that the drink contains a food additive that's been linked to an increased cancer risk.
On January 31, Oak Cliff Beverage Works issued a voluntary recall of its Beverage Base Lemonade, which was sold in three and five-gallon containers. The five-gallon products have a 'best by' date of January 1, 2026, while the three-gallon ones have a 'best by' date of December 12, 2025.
The recall involves 8,847 units of the lemonade, as noted by the Food and Drug Administration (FDA). Affected products were sold in eight states: Arkansas, California, Colorado, Kentucky, Missouri, New Mexico, Oklahoma, and Texas.
The product was recalled due to an undeclared presence of a synthetic food dye, Yellow 5, in the drink.
On February 25, the recall on the Beverage Base Lemonade was classified as a Class II recall. This classification means the recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indianapolis Star
20 minutes ago
- Indianapolis Star
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV.' While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable. 1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease, 2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults. 3 This approval was supported by results from Moderna's Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATION mRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: Have any allergies Had a severe allergic reaction after receiving a previous dose of any other vaccine Have a fever Have a bleeding disorder or are on a blood thinner Are immunocompromised or are on a medicine that affects your immune system Have received any other RSV vaccine Have ever fainted in association with an injection How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Side effects that have been reported in clinical trials with mRESVIA include: Injection-site reactions: pain, underarm swelling or tenderness in the same arm of the injection, swelling (hardness), and redness Fatigue, headache, muscle pain, joint pain, chills, nausea or vomiting, fever and hives These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc.
Yahoo
30 minutes ago
- Yahoo
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera ( in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA. The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that it has established a wholly owned subsidiary, Immuthera, a United States C Corporation, in the state of Delaware. This is a further step by PolTREG to deepen its entry into the U.S. market. 'Over recent years, PolTREG has created a platform for the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, mulit-eidited/allogeneic CAR-Tregs, antigen-specific Tregs, and mRNA immunotherapies, all informed by our clinical experience. To fully leverage our potential, we are focusing on the execution our growth strategy in the American market by systematically bringing existing therapies, and exploring new assets into the US. We have established partnerships with several renowned entities such as Noble Capital Markets, Inc., for strategic and financial advisory services. We have also formed a strategic cooperation with the Swiss company Antion Biosciences to develop the next generation of allogeneic TREG therapies' said Prof. Piotr Trzonkowski, CEO of PolTREG. 'This expands PolTREG's project pipeline and enhances the company's attractiveness to potential strategic partners. Additionally, we with the U.S. company Kinexum Services LLC for strategic advisory regarding Immuthera's interactions with the FDA and the registration of TREG therapies in the United States. We submitted our Pre-IND meeting request to the FDA in mid-May,' added Prof. Piotr Trzonkowski. PolTREG is currently in discussions with leading American academic and clinical centers to establish collaborations and evaluate new technologies Immuthera has also begun the process of building a world-class Scientific Advisory Board comprised of globally recognized leaders in the Autoimmune and Neuroinflammatory disease. In support of PolTREG and the launch of Immuthera, Dr. Dan Shelly, Chief Business Development Officer, and Dr. Mariusz Jablonski, Chief Business Officer, will participate in the upcoming BIO International Convention 2025, taking place from June 16–19 in Boston. At BIO Drs. Shelly and Jablonski will be promoting PolTREG's current clinical and developmental pipeline while also speaking to potential partners, collaborators, and investors for Immuthera. In May, the Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on the Pediatric Investigation Plan (PIP) for PolTREG's investigational somatic cell therapy product, polyclonal Treg lymphocytes (PTG-007), which is aimed to prevent symptomatic type 1 diabetes in children. The PDCO's positive opinion is based on PolTREG's original preTreg clinical trial protocol, initiated in October 2024, enrolling children aged 6–16 years with Stage 1 type 1 diabetes. In its assessment, the committee recommended broadening the eligible population to include patients aged 3–18 years suggesting that the agency believes this therapy is extremely safe. This positive opinion paves the way for potential marketing authorization in the EU. To read more about the clinical trials PolTREG has completed, please click on: PolTREG manufactures its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe's largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines. PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours. About PolTREG PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For more information please visit For further information please contact:PolTREG Piotr TrzonkowskiChief Executive Officerir@ 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.